Bexson Biomedical Obtains USPTO Patent Clearance on its Proprietary Formulation Technology, SEVALENT™


SANTA BARBARA, Calif., September 15, 2022 /PRNewswire/ — Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the market for small molecule injections and building home health solutions, today announced that the U.S. Patent Office and Trademarks (USPTO) has issued a Notice of Allowance for US Application No. 17/546,880 filed on December 9, 2021 and entitled Complexing Agent Salt Formulations of Pharmaceutical Compounds.

The Bexson formulation platform, under the SEVALENT brandMT, is the basis of the company’s ketamine therapy, BB106. The Company believes this patent grant expands the potential utility of its formulation technology, SEVALENTMT, to other small molecules. SEVALENTSMT is designed to allow intravenous (IV)-only therapies to now be delivered subcutaneously in a controlled manner for home use.

“The allocation is significant because it protects our novel salt formulation technology across a broad platform of therapeutic areas,” commented jeffrey becker, MD, Scientific Director. “There has been little innovation for the delivery of small molecule therapies, so we believe the opportunity to migrate from IV to subcutaneous delivery will be a game-changer for both patients and payers.”

“We are delighted with this advancement in building the company’s patent portfolio and achieving another important milestone in protecting our formulation technology,” said Gregg Peterson, CEO. “Furthermore, this award, along with our other patents, demonstrates our strong commitment to protecting the innovation and broad business opportunities offered by our growing product portfolio.”

Bexson Biomedical, Inc.

Bexson Biomedical, Inc. is a biopharmaceutical company focused on disrupting the small molecule injectable market and delivering home health solutions through novel formulations designed for subcutaneous administration. Bexson’s proprietary platform, SEVALENTMTcan be applied to small molecules in a wide range of drug classes, allowing IV therapies to be delivered subcutaneously.

Bexson’s primary therapy, BB106, is a low-dose ketamine treatment for postoperative pain management, a $36 billion global market and main driver of opioid addiction. Additionally, management believes that its BB106 formulation technology can be used to treat various mental health indications.

SOURCEBexson Biomedical


Comments are closed.